Together, these findings demonstrate that CDX2-reinstatement therapy drives differentiation and apoptosis selectively in CDX2-low CRC models, both in vitro and in vivo, through PRKAB1-specific activation. Here, PRKAB1 is linked to colorectal carcinoma.